202 related articles for article (PubMed ID: 34729700)
1. CD146 as a promising therapeutic target for retinal and choroidal neovascularization diseases.
Xue B; Wang P; Yu W; Feng J; Li J; Zhao R; Yang Z; Yan X; Duan H
Sci China Life Sci; 2022 Jun; 65(6):1157-1170. PubMed ID: 34729700
[TBL] [Abstract][Full Text] [Related]
2. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.
Fu Z; Gong Y; Liegl R; Wang Z; Liu CH; Meng SS; Burnim SB; Saba NJ; Fredrick TW; Morss PC; Hellstrom A; Talukdar S; Smith LE
Cell Rep; 2017 Feb; 18(7):1606-1613. PubMed ID: 28199833
[TBL] [Abstract][Full Text] [Related]
3. Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.
Wang W; LeBlanc ME; Chen X; Chen P; Ji Y; Brewer M; Tian H; Spring SR; Webster KA; Li W
Angiogenesis; 2017 Nov; 20(4):479-492. PubMed ID: 28447229
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
Eyetech Study Group
Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor therapy for ocular neovascular disease.
Andreoli CM; Miller JW
Curr Opin Ophthalmol; 2007 Nov; 18(6):502-8. PubMed ID: 18163003
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effect of dasatinib in murine models of oxygen-induced retinopathy and laser-induced choroidal neovascularization.
Seo S; Suh W
Mol Vis; 2017; 23():823-831. PubMed ID: 29225458
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathogenesis of retinal and choroidal vascular diseases.
Campochiaro PA
Prog Retin Eye Res; 2015 Nov; 49():67-81. PubMed ID: 26113211
[TBL] [Abstract][Full Text] [Related]
8. SCF (Stem Cell Factor) and cKIT Modulate Pathological Ocular Neovascularization.
Kim KL; Seo S; Kim JT; Kim J; Kim W; Yeo Y; Sung JH; Park SG; Suh W
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2120-2131. PubMed ID: 31434494
[TBL] [Abstract][Full Text] [Related]
9. VEGF-binding aptides and the inhibition of choroidal and retinal neovascularization.
Jo DH; Kim S; Kim D; Kim JH; Jon S; Kim JH
Biomaterials; 2014 Mar; 35(9):3052-9. PubMed ID: 24388818
[TBL] [Abstract][Full Text] [Related]
10. Both Autocrine Signaling and Paracrine Signaling of HB-EGF Enhance Ocular Neovascularization.
Inoue Y; Shimazawa M; Nakamura S; Takata S; Hashimoto Y; Izawa H; Masuda T; Tsuruma K; Sakaue T; Nakayama H; Higashiyama S; Hara H
Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):174-185. PubMed ID: 29191924
[TBL] [Abstract][Full Text] [Related]
11. Apatinib, an Inhibitor of Vascular Endothelial Growth Factor Receptor 2, Suppresses Pathologic Ocular Neovascularization in Mice.
Kim KL; Suh W
Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3592-3599. PubMed ID: 28715845
[TBL] [Abstract][Full Text] [Related]
12. microRNA-181a inhibits ocular neovascularization by interfering with vascular endothelial growth factor expression.
Yang C; Tahiri H; Cai C; Gu M; Gagnon C; Hardy P
Cardiovasc Ther; 2018 Jun; 36(3):e12329. PubMed ID: 29608244
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of CD146 attenuates retinal neovascularization via vascular endothelial growth factor receptor 2 signalling pathway in proliferative diabetic retinopathy.
Lin J; Cui K; Xu Y; Tang X; Shi Y; Lu X; Yang B; He Q; Yu S; Liang X
Acta Ophthalmol; 2022 Jun; 100(4):e899-e911. PubMed ID: 34477295
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.
Gong Y; Shao Z; Fu Z; Edin ML; Sun Y; Liegl RG; Wang Z; Liu CH; Burnim SB; Meng SS; Lih FB; SanGiovanni JP; Zeldin DC; Hellström A; Smith LEH
EBioMedicine; 2016 Nov; 13():201-211. PubMed ID: 27720395
[TBL] [Abstract][Full Text] [Related]
15. Systemic rapamycin inhibits retinal and choroidal neovascularization in mice.
Dejneka NS; Kuroki AM; Fosnot J; Tang W; Tolentino MJ; Bennett J
Mol Vis; 2004 Dec; 10():964-72. PubMed ID: 15623986
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide, an anti-tumor drug, regulates retinal endothelial cell function: Implication for treating ocular neovascular disorder.
Dong LF; Yao J; Wang XQ; Shan K; Yang H; Yan B; Jiang Q
Biochem Biophys Res Commun; 2015 Oct; 465(4):678-84. PubMed ID: 26255966
[TBL] [Abstract][Full Text] [Related]
17. Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A.
Dong A; Seidel C; Snell D; Ekawardhani S; Ahlskog JK; Baumann M; Shen J; Iwase T; Tian J; Stevens R; Hackett SF; Stumpp MT; Campochiaro PA
Angiogenesis; 2014 Jul; 17(3):553-62. PubMed ID: 24154861
[TBL] [Abstract][Full Text] [Related]
18. Myeloid-Derived Vascular Endothelial Growth Factor and Hypoxia-Inducible Factor Are Dispensable for Ocular Neovascularization--Brief Report.
Liyanage SE; Fantin A; Villacampa P; Lange CA; Denti L; Cristante E; Smith AJ; Ali RR; Luhmann UF; Bainbridge JW; Ruhrberg C
Arterioscler Thromb Vasc Biol; 2016 Jan; 36(1):19-24. PubMed ID: 26603154
[TBL] [Abstract][Full Text] [Related]
19. Differential hypoxic response of human choroidal and retinal endothelial cells proposes tissue heterogeneity of ocular angiogenesis.
Mammadzada P; Gudmundsson J; Kvanta A; André H
Acta Ophthalmol; 2016 Dec; 94(8):805-814. PubMed ID: 27255568
[TBL] [Abstract][Full Text] [Related]
20. Nrf2 Activator RS9 Suppresses Pathological Ocular Angiogenesis and Hyperpermeability.
Nakamura S; Noguchi T; Inoue Y; Sakurai S; Nishinaka A; Hida Y; Masuda T; Nakagami Y; Horai N; Tsusaki H; Hara H; Shimazawa M
Invest Ophthalmol Vis Sci; 2019 May; 60(6):1943-1952. PubMed ID: 31050722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
